Amylyx Pharmaceuticals, Inc.
AMLXNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | $0 | $87.4M | $380.8M | $22.2M | $285,000 |
| Operating income | −$153.3M | −$314.7M | $38.8M | −$201.3M | −$82.7M |
| Net income | −$144.7M | −$301.7M | $49.3M | −$198.4M | −$87.9M |
| Total assets | $332.6M | $193.6M | $517.5M | $391.5M | $105.6M |
| Total liabilities | $27.4M | $28.9M | $84.0M | $50.8M | $17.4M |
| Equity | $305.3M | $164.8M | $433.4M | $340.6M | −$151.2M |
| EPS (diluted) | $-1.53 | $-4.43 | $0.70 | $-3.39 | $-13.35 |
| Shares out. | 88.6M | 67.8M | 66.7M | 66.5M | 7.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −47.4%
- Return on assets
- −43.5%
- Return on capital (ROCE)
- −49.5%
- Liabilities / assets
- 8.2%
- Debt / equity
- 0.09×
- Book value / share
- $3.45
- Revenue growth (YoY)
- −100.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 7.18safe
- Accruals / assets
- −6.4%clean
- Piotroski F-Score
- 4/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 warning● 3 good- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- RELYVRIOSep 29, 2022
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2024-01-19Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
- Phase 2Active Not Recruitingreadout ~2024-07-23AMX0035 in Adult Patients With Wolfram Syndrome
- Phase 3Active Not Recruitingreadout ~2026-03Avexitide for Treatment of Post-Bariatric Hypoglycemia
- Phase 1Recruitingreadout ~2027-02AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 14.5M | 12.2 | -1.9% |
| Apr 30, 2026 | 14.8M | 14.3 | -0.2% |
| Apr 15, 2026 | 14.8M | 12.2 | +4.2% |
| Mar 31, 2026 | 14.2M | 14.1 | +2.6% |
| Mar 13, 2026 | 13.9M | 12.5 | -4.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.